CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Kendle , a leading, global full-service clinical research organization (CRO), today announced the appointment of Philip J.W. Davies to the position of Vice President, Phase I. Davies will provide global leadership to strengthen and grow the company's Phase I business which includes a Clinical Pharmacology Unit in The Netherlands and a bioequivalence unit in West Virginia, and will focus on expanding Phase I capabilities globally. Davies will be based in Kendle's Cincinnati headquarters and will report directly to Candace Kendle, PharmD, Chairman and Chief Executive Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
"Phase I is a rapidly growing area of opportunity and is an integral part of Kendle's business plan, with the market expected to grow between 13.4 and 16 percent annually through 2010," said Dr. Kendle. "I am pleased to welcome Phil to this key leadership role as Kendle focuses on the strategic expansion of our early stage capabilities to meet our customers' needs."
Davies brings more than two decades of pharmacology expertise to this position. He joins Kendle from Eli Lilly and Company where he served most recently as Director of Global Exploratory and Program Phase Medical Operations. He has been with Eli Lilly since 2001, serving in multiple roles of increasing responsibility, including Director, Global Exploratory Medicine Operations; Director, Global Clinical Pharmacology Operations; and Director, U.S. Clinical Pharmacology Operations. Prior to Eli Lilly, Davies served as Director of Kendle's Clinical Pharmacology Unit in The Netherlands and previously held Clinical Pharmacology roles in Germany and the UK.
About Kendle
Kendle International Inc. is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions -- from first-in-human studies through market launch and surveillance -- to help the world's biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions -- North America, Europe, Asia/Pacific, Latin America and Africa -- to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at www.kendle.com.
Forward-Looking Statements
This release contains information about management's view of Kendle's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the "Risk Factors" section of the Company's latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point, the Company specifically disclaims any obligation to do so other than as required by federal securities laws. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
CONTACT: Investors, Patty Frank, +1-513-763-1992, or Media, Lori Dorer,
+1-513-345-1685, both of Kendle International Inc.
Web site: http://www.kendle.com/
